Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
GlobalData Clinical Trials Report Coverage 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Clinical Trials by G7 Countries: Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials 16
Clinical Trials in E7 Countries by Trial Status 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Top Companies Participating in Primary Systemic Amyloidosis Therapeutics Clinical Trials 25
Prominent Drugs 26
Clinical Trial Profile Snapshots 27
Appendix 53
Abbreviations 53
Definitions 53
Research Methodology 54
Secondary Research 54
About GlobalData 55
Contact Us 55
Source 55

List of Tables
Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Region, 2018* 6
Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 7
Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 8
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2018* 9
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 10
Primary Systemic Amyloidosis Therapeutics Clinical Trials, North America, Top Countries, 2018* 11
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 12
Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials, G7 Countries (%), 2018* 13
Primary Systemic Amyloidosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 14
Primary Systemic Amyloidosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 15
Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials, E7 Countries (%), 2018* 16
Primary Systemic Amyloidosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 17
Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Phase, 2018* 18
Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 19
Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Trial Status, 2018* 20
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, by End Point Status, 2018* 21
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 22
Primary Systemic Amyloidosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 23
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 24
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 25
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 26

List of Figures
Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Region (%), 2018* 6
Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 7
Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 8
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2018* 9
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 10
Primary Systemic Amyloidosis Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 11
Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials, G7 Countries (%), 2018* 13
Primary Systemic Amyloidosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 14
Primary Systemic Amyloidosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 15
Proportion of Primary Systemic Amyloidosis to Metabolic Disorders Clinical Trials, E7 Countries (%), 2018* 16
Primary Systemic Amyloidosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 17
Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Phase (%), 2018* 18
Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 19
Primary Systemic Amyloidosis Therapeutics, Global, Clinical Trials by Trial Status, 2018* 20
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, by End Point Status, 2018* 21
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 22
Primary Systemic Amyloidosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 23
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 24
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 25
Primary Systemic Amyloidosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 26
GlobalData Methodology 54

Companies Mentioned
- Celgene Corp
- Prothena Corp Plc
- Johnson & Johnson
- Takeda Pharmaceutical Co Ltd
- TheraPharm Deutschland GmbH
- Spectrum Pharmaceuticals Inc
- GlaxoSmithKline Plc
- Bristol-Myers Squibb Co
- Amgen Inc